Phase i study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue

Clinical Cancer Research

Volumn 2, Issue 7, 1996, Pages 1123-1127

  Sessa, Cristiana ^a   De Jong, Jolanda ^a   D'Incalci, Maurizio ^b   Hatty, Sarah ^c   Pagani, Olivia ^a   Cavalli, Franco ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOMETREXOL; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; ENZYME INHIBITION; FEMALE; FOLIC ACID DEFICIENCY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PURINE SYNTHESIS; THROMBOCYTOPENIA;

ADULT; BONE MARROW; FOLIC ACID ANTAGONISTS; HUMANS; LEUCOVORIN; NEOPLASMS; TETRAHYDROFOLATES;

EID: 0030007680     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Beardsley, G. P., Moroson, B. A., Taylor, E. C., and Moran, A. G. A new folate antimetabolite 5,10-dideaza-5,6,7,8-tetrahydrofolate is a potent inhibitor of de novo purine synthesis. J Biol. Chem., 264: 328-333, 1989.
2. Lometrexol LY 264618 Clinical Investigator Brochure, Eli Lilly, Indianapolis, p. 3.2, 1992.
3. Nelson, R., Butler, F., Dugan, W., Jr., Davisland, C., Stone, M., and Dyke, R. Phase I clinical trial of LY 264618 (dideazatetrahydrofolic acid: DDATHF). Proc. Am. Soc. Clin. Oncol., 9: 76, 1990.
4. Ray, M., Muggia, F. M., Leichman, C. G., Grunberg, S. M., Nelson, R. L., Dyke, R. W., and Moran, R. G., Phase I study of (6R)-5,10-dideazatetrahydrofolate, a folate antimetabolite inhibitory to de novo purine synthesis. J. Natl. Cancer Inst., 85: 1154-1159, 1993.
5. Miller, A. B., Hoogstraten, B., Staquet, M., and Winkler, A. Reporting results of cancer treatment. Cancer (Phila.). 47: 207-214, 1981.
6. Wedge, S. R., Laohavinij, S., Taylor, G. A., and Newell, D R. Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography. J. Chrom. Biomed Appl., 663: 327-335, 1995.
7. Wedge, S. R., Laohavinij, S., Taylor, G. A., Boddy, A., Calvert, A. H., and Newell, D. R. Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin. Cancer Res., 1: 1479-1486, 1995.
8. Miotti, S., Canevari, S., Menard, S., Mezzanzanica, D., Porro, G., Pupa, S. M., Regazzoni, M., Tagliabue, E., and Colnaghi, M. I. Characterization of human ovarian cancer carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. J. Cancer, 39: 297-303, 1987.
9. Miotti, S., Alberti, S., Facheris, P., Mantovani, L., Fornaro, M., Stella, M., Menard, S., Canevari, S., and Colnaghi, M. I. Membrane association and shedding of the GP-anchored Ca-Mov18 antigen in human ovary carcinoma cells. Int. J. Cancer, 51: 499-505, 1992.
10. Sen, S., Erba, E., D'Incalci, M., Bottero, F., Canevari, S., and Tomassetti, A. Role of membrane folate binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro. Br. J. Cancer, 73: 525-530, 1995.
11. Grindey, G. B., Alati, T., and Shih, C. Reversal of the toxicity but not the antitumour activity of lometrexol by folic acid. Proc. Am. Assoc. Cancer Res., 32: 324, 1991.
12. 3H mice. Lometrexol LY 264618 Clinical Investigational Brochure, Eli Lilly, Indianapolis, p. 3.16, 1992.
13. Alati, T., Shih, C., Pohland, R. C., Lantz, R. J., and Grindey, G B. Evaluation of the mechanism(s) of inhibition of the toxicity, but not the antitumour activity of lometrexol (DDATHF) by folic acid. Proc. Am. Assoc. Cancer Res., 33: 407, 1992
14. Wedge, S. R., Laohavinij, S., Taylor, G. A , Newell, D. R., Charlton, C. J., Proctor, M., Simmons, D., Oakey, A., Gumbrell, L., and Calvert, A. H. Modulation of lometrexol toxicity by oral folic acid administration: a Phase I study. Proc. Am. Assoc. Cancer Res., 34: 274, 1993
15. Pizzorno, G., Moroson, B. A., Cashmore, A R., Russello, O., Mayer, J R., Galivan, J., Bunni, M. A., Priest, D. G., and Beardsley, G. P. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res., 55: 556-573, 1995.
16. Erba, E., Sen, S., Sessa, C., Vinkhanskaya, F. L., and D'Incalci, M. Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Br. J. Cancer, 69: 205-211, 1994.
17. Worzalla, J. F., Rutheford, P. G., Self, T. D., Seymour, P. D., Theobald, K S., Mendelsohn, L. G., Gossett, L. S., Shih, C., Schultz, R. M., and Grindey, G. B. In vivo antitumour activity of LY 309887, a new antifolate inhibitor of glycinamide ribonucleotide formyl transferase. Proc. Am. Assoc. Cancer Res., 36: 378, 1995.